JP2010510223A - Ｔｉｍ−３調節物質の治療的使用 - Google Patents

Ｔｉｍ−３調節物質の治療的使用 Download PDF

Info

Publication number
JP2010510223A
JP2010510223A JP2009537223A JP2009537223A JP2010510223A JP 2010510223 A JP2010510223 A JP 2010510223A JP 2009537223 A JP2009537223 A JP 2009537223A JP 2009537223 A JP2009537223 A JP 2009537223A JP 2010510223 A JP2010510223 A JP 2010510223A
Authority
JP
Japan
Prior art keywords
tim
agent
polypeptide
galectin
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009537223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510223A5 (enExample
Inventor
デヴィッド イー． アンダーソン
アナ シー． アンダーソン
ヴィジェイ ケー． クチュルー
デヴィッド エー． ハフラー
Original Assignee
サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド filed Critical サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド
Publication of JP2010510223A publication Critical patent/JP2010510223A/ja
Publication of JP2010510223A5 publication Critical patent/JP2010510223A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
JP2009537223A 2006-11-15 2007-11-15 Ｔｉｍ−３調節物質の治療的使用 Withdrawn JP2010510223A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85939106P 2006-11-15 2006-11-15
US92394507P 2007-04-17 2007-04-17
PCT/US2007/024067 WO2008060617A2 (en) 2006-11-15 2007-11-15 Therapeutic uses of tim-3 modulators

Publications (2)

Publication Number Publication Date
JP2010510223A true JP2010510223A (ja) 2010-04-02
JP2010510223A5 JP2010510223A5 (enExample) 2012-01-26

Family

ID=39402274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537223A Withdrawn JP2010510223A (ja) 2006-11-15 2007-11-15 Ｔｉｍ−３調節物質の治療的使用

Country Status (6)

Country Link
US (1) US20100061992A1 (enExample)
EP (1) EP2081961A2 (enExample)
JP (1) JP2010510223A (enExample)
AU (1) AU2007319806A1 (enExample)
CA (1) CA2668693A1 (enExample)
WO (1) WO2008060617A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JP2015535259A (ja) * 2012-10-29 2015-12-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 新規粘膜アジュバントおよびデリバリーシステム
JP2019507194A (ja) * 2016-03-04 2019-03-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
JP2019518787A (ja) * 2016-05-13 2019-07-04 ユニベルシテ ド ロレーヌＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｏｒｒａｉｎｅ ガレクチンのｃｒｄのレクチン活性に基づく組換えタンパク質のアフィニティー精製のための方法
WO2021172889A1 (ko) * 2020-02-25 2021-09-02 국립암센터 Cd11b+ 세포에서 tim-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
AU2010229835B2 (en) * 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CA2916638C (en) * 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
JP6356134B2 (ja) 2012-10-12 2018-07-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の増強
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
WO2016171722A1 (en) * 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016179194A1 (en) * 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
AU2018265571B2 (en) 2017-05-12 2022-09-29 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
AU2022274001A1 (en) * 2021-05-11 2023-12-21 Griffith University Immunogenic composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
EP1685159B1 (en) * 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556270B2 (en) 2010-06-11 2017-01-31 Kyowa Hakko Kirin Co., Ltd Anti-TIM-3 antibody
US10550181B2 (en) 2010-06-11 2020-02-04 Kyowa Kirin Co., Ltd Anti-TIM-3 antibody
US8552156B2 (en) 2010-06-11 2013-10-08 Kyowa Hakko Kirin Co., Ltd Anti-TIM-3 antibody
AU2011262758B2 (en) * 2010-06-11 2014-04-24 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
AU2011262758A8 (en) * 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
JP2017189168A (ja) * 2010-06-11 2017-10-19 協和発酵キリン株式会社 抗ｔｉｍ−３抗体
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JPWO2011155607A1 (ja) * 2010-06-11 2013-08-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体
JP2015535259A (ja) * 2012-10-29 2015-12-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 新規粘膜アジュバントおよびデリバリーシステム
JP7086008B2 (ja) 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
JP2019507194A (ja) * 2016-03-04 2019-03-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
JP2019518787A (ja) * 2016-05-13 2019-07-04 ユニベルシテ ド ロレーヌＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｏｒｒａｉｎｅ ガレクチンのｃｒｄのレクチン活性に基づく組換えタンパク質のアフィニティー精製のための方法
JP7105761B2 (ja) 2016-05-13 2022-07-25 ユニベルシテ ド ロレーヌ ガレクチンのｃｒｄのレクチン活性に基づく組換えタンパク質のアフィニティー精製のための方法
WO2021172889A1 (ko) * 2020-02-25 2021-09-02 국립암센터 Cd11b+ 세포에서 tim-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법

Also Published As

Publication number Publication date
EP2081961A2 (en) 2009-07-29
CA2668693A1 (en) 2008-05-22
WO2008060617A3 (en) 2008-12-24
WO2008060617A2 (en) 2008-05-22
US20100061992A1 (en) 2010-03-11
AU2007319806A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
US20100061992A1 (en) Therapeutic uses of tim-3 modulators
AU2022200016B2 (en) Cancer vaccines and methods of treatment using the same
JP4903128B2 (ja) Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法
AU2013312211B2 (en) VISTA modulators for diagnosis and treatment of cancer
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US10703817B2 (en) System for delivery into XCR1 positive cell and uses thereof
JP2022034067A (ja) Ｔ細胞調節方法
KR20190102267A (ko) Psgl-1 길항제 및 그의 용도
EP3470081A1 (en) Methods for treating cancer in patients with elevated levels of bim
ES2939112T3 (es) Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
EP1333850B1 (en) Use of il-13 inhibitors for the treatment of tumors
JP2022525223A (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
WO2016141312A1 (en) Beta-catenin inhibitors in cancer immunotherapy
EP1615670A2 (en) Targets for tumor growth inhibition
US20210379147A1 (en) Method and system for treating cancer utilizing tinagl1
US9688732B2 (en) Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
JP2022546023A (ja) Ｔｎｆｒｓｆ２５抗体を用いた癌の治療方法
US20250367289A1 (en) Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
US20230340127A1 (en) Methods and compositions for cancer treatment by inhibition of fbxo44
CN101027392B (zh) 通过调节tim-1、tim-2和tim-4功能从而调节免疫应答的方法
US20100297146A1 (en) Immune system programming through b7-dc
Winograd Induction of T Cell Immunity Overcomes Resistance to Pd-1 and Ctla-4 Blockade and Improves Survival in Pancreatic Cancer
Adams of the International Society for Biological Therapy of Cancer (now the Society for Immunotherapy of Cancer)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111114

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120516